Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?

Apr 22 2021

• By Tara Hansen

Car gas and brake pedals

Related Content

Accelerated Approval: US FDA Review Of Expedited Program Could Bring More Withdrawals

Feb 24 2021

Keeping Track: Novel Orphan Drugs Amondys 45, Nulibry Clear US FDA; First-Line NSCLC Claim For Libtayo

Feb 27 2021

Conflicts Galore: Upcoming Accelerated Approval Cancer Panel Includes Many Industry Relationships

Apr 22 2021

Accelerated Approval: US FDA Panel To Reconsider Six Indications For Checkpoint Inhibitors

Mar 12 2021

Related Companies

Genentech, Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

AstraZeneca PLC

Pfizer Inc.

Regeneron Pharmaceuticals, Inc.

Sanofi

Additional Topics

United States Review Pathway Post Market Regulation & Studies Regulation Drug Review Cancer BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window